Marketing of ointment by M|s. Warner Hindustan

2198. SHRI SYED RAHMAT ALI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 189 given in the Rajya Sabha on 18th November, 1985 and state:

(a) what are the basis on which M|s. Warner Hindustan is marketing Anusol, Anusol-H and Anugesic-HC ointment under price exempted category;

(b) whether it is a fact that these products contain Zinc Oxide and are being marketed as darmatulogical preparations by the company;

(c) if so, how Government did not categorise these drugs falling under category III of Drugs Price Control Order;

(d) whether it is also a fact that two of these products contain Hydrocortisone which is covered under category III;

(e) if so, why the company did not apply for price approval; and

(f) what action has been taken by Government against the company for enjoying the undue profits at the cost of poor consumer?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Anusol, Anusol-H and Anugesic-HC Ointment being Heamorrihoidal preparations are in category IV of the 1978 Drug Policy.

(b) Although one of the ingredients in the three preparations is Zinc Oxide yet the products are not dermatological preparations as per details made available by M|s. Warner Hindustan Limited.

(c) to (f) Reasons for treating the three products as price decontrolled products are explained in reply to part (a).

Exports of drug by M|s. Abbott Laboratories

2199. SHRI SYED RAHMAT ALI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 207 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) what are the names of the products exported by M|s Abbott Laboratories during 1984;

(b) what was their export from 1st January to 31st October, 1985 along with names of the products;

(c) how many of the products exported during 1984 and 1985 fall under the list of products for which re-endorsement of capacity was allowed and what is the value of those products;

(d) what was the value of exports of Abbott during 1980, 81, 82, 83 along with names of products;

(e) what is the value of the production of formulations of re-endorsed capacity during the last three years, yearwise along with quantity and name of each product; and

(f) what is the present position of ratio parameter of this company and what were the basis of departure from drug Policy to allow re-endorsement of capacity to this company?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (d) The information to the extent available is given in the statement annexed (*See below*).

(e) Desired details are not available.

(f) The Company does not satisfy the ratio parameters. There has been no departure from the policy in regard to re-endorsement of capacities under the April, 1982 Scheme.

Statement

As reported by M/s. Abbott Labs. the details of products and value of exports during 1st September, 1984 to 31st October, 1985 are given below

PRODUCTS COVERED UNDER RE-ENDORSEMENT OF CAPACITY

	Name of the Product	Value (FOB) (Rs.)
1.	Cecon	46,777
2.	Erythrocin Granules	7,66,031
3.	Iberol Tablets (100's bottle)	90,323
4.	Iberol Tablets (25's bottle)	40,620
5.	Iberol '500' Tonic (90 ml. bottle)	24,281
6.	Kaltin with Neomycin	3,12,450
7.	Selsun 1%	8,34,644
8.	Selsun 2-1/2%	5,25,184
9.	Surbex T Tab. (100 ' bottle)	45,080
10.	Surbex T Tab. (25's bottle)	14,236
11.	Vidaylin-M Syrup (90 ml. bottle)	3,75,166
12.	Vidaylin-M Syrup (240 ml. bottle)	1,29,902
13.	Vidaylin-M Drops (15 ml. bottle)	90,618

PRODUCTS NOT COVERED UNDER RE-ENDORSEMENT OF CAPACITY

1.	Citrosoda	2,11,303
2.	Kaolin Mixture with Pectin	1,54,786
3.	Pentothal Sodium 1·0 gm.	5,35,224
4.	Pentothal Sodium 0·5 gm.	47,983

Production of bulk drugs by foreign companies

2200. SHRI SYED RAHMAT ALI: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 195 given in the Rajya Sabha on the 18th November 1985 and state:

(a) whether it is a fact that Government have respected the recommendation of Hathi Committee for production of bulk drugs from basic stages within a period of two years by foreign companies which they were importing or producing from intermediate stages during 1978;

(b) whether it is a fact that such provision is covered under Drug Policy, 1978; and

(c) if so, what steps were taken to implement this provision?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) The Government have accepted the recommendation of the Hathi Committee that foreign comapnies producing bulk drugs from penultimate stage will have to manufacture the same from the basic stage within a period of two years.

(c) In the absence of any provision under the I (D&R) Act, 1951 to call back the existing industrial licences and impose fresh conditions thereon, the policy decision contained in paragraph